{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:36:47Z","timestamp":1783769807492,"version":"3.55.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2023-KH134527"],"award-info":[{"award-number":["RS-2023-KH134527"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.parkreldis.2025.108136","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T07:34:51Z","timestamp":1764574491000},"page":"108136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Association between cognitive adverse effects of anticholinergic medication and development of dementia in Parkinson's disease"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3981-2308","authenticated-orcid":false,"given":"Su Hyeon","family":"Ha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungmin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Ah","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hwan","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8219-9663","authenticated-orcid":false,"given":"Han-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2025.108136_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-21093-8","article-title":"High risk of developing dementia in Parkinson's disease: a Swedish registry-based study","volume":"12","author":"\u00c5str\u00f6m","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.parkreldis.2025.108136_bib2","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1007\/s00259-016-3349-x","article-title":"Cholinergic imaging in dementia spectrum disorders","volume":"43","author":"Roy","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.parkreldis.2025.108136_bib3","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/mdc3.13347","article-title":"Antimuscarinic anticholinergic medications in parkinson disease: to prescribe or deprescribe?","volume":"8","author":"Barrett","year":"2021","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2025.108136_bib4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","article-title":"Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study","volume":"175","author":"Gray","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.parkreldis.2025.108136_bib5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.parkreldis.2019.06.022","article-title":"Antiparkinsonism anticholinergics increase dementia risk in patients with parkinson's disease","volume":"65","author":"Hong","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2025.108136_bib6","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S1474-4422(12)70191-6","article-title":"Cognitive reserve in ageing and alzheimer's disease","volume":"11","author":"Stern","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2025.108136_bib7","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/13825585.2021.1892026","article-title":"Cognitive reserve: a multidimensional protective factor in parkinson's disease related cognitive impairment","volume":"29","author":"Ciccarelli","year":"2022","journal-title":"Neuropsychol Dev Cogn B Aging Neuropsychol Cogn"},{"key":"10.1016\/j.parkreldis.2025.108136_bib8","doi-asserted-by":"crossref","first-page":"646","DOI":"10.14283\/jpad.2022.55","volume":"9","author":"Moga","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.parkreldis.2025.108136_bib9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40801-025-00509-7","article-title":"CALS and ACB scales are associated with physical and cognitive impairment and predict mortality in nursing home residents","volume":"12","author":"Soraci","year":"2025","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.parkreldis.2025.108136_bib10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00002512-199710050-00005","article-title":"Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment","volume":"10","author":"Young","year":"1997","journal-title":"Drugs Aging"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802025008855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802025008855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T18:05:35Z","timestamp":1773857135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802025008855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":10,"alternative-id":["S1353802025008855"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2025.108136","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between cognitive adverse effects of anticholinergic medication and development of dementia in Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2025.108136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108136"}}